Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease

Trial Profile

A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 02 Jul 2019

At a glance

  • Drugs Atabecestat (Primary) ; Gantenerumab (Primary) ; Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms DIAN-TU
  • Most Recent Events

    • 26 Feb 2019 Planned number of patients changed from 438 to 490.
    • 26 Feb 2019 Planned End Date changed from 1 Dec 2023 to 1 Mar 2021.
    • 26 Feb 2019 Planned primary completion date changed from 1 Sep 2023 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top